Novel Anticoagulants
|
|
- Meredith Houston
- 8 years ago
- Views:
Transcription
1 Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy, NY
2 Novel Oral Anticoagulants Novel Oral Anticoagulants Dabigatran-Pradaxa Rivaroxaban-Xarelto Apixaban-Eliquis
3 Categories Vitamin K antagonists Coumarin Heparin and derivativesactivate antithrombin III LMWH Factor Xa inhibitors Fondaparinux- Arixtra Rivaroxaban-Xarelto Apxaban-Eliquis Edoxaban-Savaysa Thrombin inhibitors Hirudin- Lepirudin Bivalirudin Argatoban Dabigatran-Pradaxa Other Batroxobin- Hementin-
4 Warfarin and its issues Patient compliance issues Narrow therapeutic index Slow onset and offset of action Dietary interactions Drug interactions Need for monitoring Non adherence leads to 30-50% of treatment failures
5 Pharmacokinetics of NOACs Action Dose Dabigatran (Pradaxa) Direct Thrombin Inhibition 150 mg BID, 75 mg BID for GFR ml/min Rivaroxaban Xareltro Activated Factor Xa Inhibitor 20 mg qd 15 mg qd for GFR ml/min Apixaban Eliquis t 1/ hrs 5-13 hrs 12 hrs Clearance 80% renal 60% renal 35% biliary Metabolism Conjugation to active glucuronides CYP3A4 CYP2J2 Activated Factor Xa Inhibitor 5 mg BID 2.5 mg BID for age>80, wt < 60 kg, Cr >1.5 25% renal 75% biliary CYP3A4 P-GP Interact Yes Yes Minimal
6 Classes of Direct Thrombin Bivalent (all IV): Hirudin Bivalrudin Lepirudin Desirudin Inhibitors Univalent Discovered 1884 Argatroban (IV) John Berry Haycraft Melagatran (prodrug Ximelagatran-development stopped) Dabigatran (oral)-pradaxa
7 Dabigatran Xa inhibitors By Joe D (Own work) [GFDL ( CC-BY-SA-3.0 ( or CC-BY-SA ( via Wikimedia Commons
8 What does thrombin do? Forms a clot, and then stabilizes it Stimulates the generation of more thrombin Inhibits fibrinolysis by stimulating thrombus activated fibrinolysis inhibitor (TAFI) Activates platelets
9 What does Factor Xa do? Trypsin-like serine protease Links the intrinsic and extrinsic pathways Converts prothrombin to thrombin
10 What is Dabigatran approved for? United States: Prevention of stroke in patients with non-valvular atrial fibrillation Treatment of VTE (April 2014) and extended treatment to prevent recurrent VTE Europe and Canada: Prevention of thromboembolic disease following hip or knee replacement surgery Non-valvular atrial fibrillation
11 What are Factor Xa Inhibitors approved for? Apixiban: Atrial Fibrillation VTE prophylaxis New drug application submitted for VTE treatment Rivaroxaban: DVT/PE treatment VTE prophylaxis Atrial fibrillation
12 Dabigatran Clinical Trials DVT prophylaxis: 2005: BISTRO II-Europe, South Africa 2007: RE-NOVATE, RE-MODEL-Europe, Australia, South Africa 2008: RE-MOBILIZE-US, Canada, Mexico, UK Atrial Fibrillation: 2007: PETRO-Europe, US 2009-ongoing: RE-LY-44 countries Venous Thrombosis: 2009: RECOVER 2011: RECOVER II, RESONATE, REMEDY Acute and Post-coronary syndromes and post-mi: 2009: REDEEM
13 Major Clinical Trials: Dabigatran DVT prophylaxis (all double blind) Dabigatran v. Enoxaparin RENOVATE 220 D 220 mg qd v. E 40 mg x d RENOVATE 150 D 150 mg qd v. E 40 mg x d RENOVATE II D 220 mg qd v. E 40 mg x d REMODEL 220 D 220 mg qd v. E 40 mg x 6-10d REMODEL 150 D 150 mg qd v. E 40 mg x 6-10d Dosing* Indication** VTE Major Bleeds REMOBILIZE 220 D 220 mg qd v. E 30 mg BID x 12-15d THR D: 6.0% E: 6.7% THR D: 8.5% E: 6.7% THR D: 7.7% E: 8.8% TKR D: 36.4% E: 37.7% TKR D: 40.5% E: 37.7% D: 1.3% E: 2.0% D: 1.6% E: 2.0% European dosing regimen: Noninferior to Enoxaparin TKR D: 31% E: 25% US dosing regimen: Inferior to Enoxaparin REMOBILIZE 150 D150mg qd v. E 30 mg BID x 12-15d TKR D: 34% E: 25% D: 1.4% E: 0.9% D: 1.5% E: 1.3% D: 1.3% E: 1.3% D: 1.5% E: 1.3% D: 0.6% E: 1.4% *D=Dabigatran, E=Enoxaparin ** Total hip replacement=thr, total knee replacement=tkr
14 Major Clinical Trials: Dabigatran VTE treatment (all double blind) Trial Dosing* Indication Recurrent VTE RECOVER II** (not fully published) D 150mg BID v. W INR for 6 months RESONATE D 150 mg BID v. PLACEBO Acute proximal DVT/PE Secondary prevention after 6-18 mos treatment of VTE D: 2.4% W: 2.2% D: 0.4% P: 5.6% Major Bleeds* RECOVER** D 150mg BID v. Acute proximal D: 2.4% D: 1.6% Noninferior, equal major bleeds, fewer minor bleeds, more W INR for 6 DVT/PE W: 2.1% W: 1.9% months dyspepsia and drug discontinuation D: 1.2% W: 1.6% D: 0.3% P: 0.0% Equal to warfarin, with less major or clinically relevant REMEDY D 150mg BID v. Secondary prevention D: 1.8% D: 0.9% bleeding, more W INR effective for than after 3-12 placebo, mos W: but 1.3% higher W: 1.8% risk than 6-36 mos treatment of VTE placebo *D=Dabigatran, W=Warfarin, P=Placebo ** After initial parenteral anticoagulation
15 Factor Xa Trials Trial Dosing* Indication Recurrent VTE EINSTEIN R 15mg BID x 3 wks then 20 qd v. W INR EINSTEIN-PE R 15mg BID x 3 wks then 20 qd v. W INR EINSTEIN- EXTEND AMPLIFY-EXT R 20mg daily v. PLACEBO A 2.5 mg or 5.0mg BID v. PLACEBO Acute proximal DVT R: 2.1% W: 3.0% PE R: 2.1% W: 1.8% Secondary prevention after 6-12 mos treatment of VTE Secondary prevention after 6-12 mos treatment of VTE R: 1.3% P: 7.1% A(2.5): 1.7% A(5.0): 1.7% P: 8.8% Major Bleeds* R: 0.8% W: 1.2% R: 1.1% W: 2.2% R: 0.7% P: 0.0% A(2.5): 0.2% A(5.0): 0.1% P: 0.5%% R=Rivaroxaban, A= Apixaban, W=Warfarin, P=Placebo
16 Factor Xa Clinical Trials DVT prophylaxis: 2008: RECORD 1,2,3 (Rivaroxaban knee, hip, hip) : ADVANCE 1,2,3 (Apixaban knee, knee, hip) Atrial Fibrillation: 2011: ROCKET-AF (Rivaroxaban) 2011: ARISTOTLE (Apixiban) Venous Thrombosis (DVT/PE): 2010: EINSTEIN (Rivaroxaban) 2012: EINSTEIN-PE (Rivaroxaban) 2013: EINSTEIN-EXTEND (Rivaroxaban) AMPLIFY (Apixiban) AMPLIFY-EXT (Apixiban) Superior, fewer bleeds (knees) Superior, with European Dosing, inferior with US Noninferior, fewer dosing fatal bleeds Superior, fewer bleeds, death Noninferior Noninferior, fewer bleeds in PE trial Superior, more bleeds than placebo Noninferior, fewer bleeds Superior, more bleeds than placebo
17 Atrial Fibrillation Post-approval monitoring for Dabigatran: 1.6 bleeding events per 100,000 days risk: NEJM 2013:368:14-15 AHA/ACC Guidelines for Stroke prophylaxis for atrial fibrillation:» Warfarin Class I A» Dabigatran Class IB» Rivaroxaban Class IIb B» Apixaban Class IB
18 Dabigatran and Atrial Fibrillation RE-LY Trial: NEJM 2009:361: Stroke prevention 18,113 patients at a > 2.5% per year estimated risk for CVA (CHADS 2 score) randomized to warfarin (INR goal 2-3) v. Dabigatran 110 BID or 150 BID Dabigatran 150 BID dosing 1.53% per year risk of CVA or embolism compared to 1.6% per year for warfarin (CI , p<0.001 for non-inferiority) Major bleeding 3.11% v. 3.36% (p=0.31), Mortality equivalent Hemorrhagic stroke 0.10% v. 0.38% (p<0.01) Contraindicated in patients with prosthetic heart valves
19 Atrial Fibrillation Trials Trial Dosing* Indication Primary endpoints RELY Superior (RR 0.66, p<0.001, equal major bleeds) ROCKET-AF D 150mg BID D 110mg BID W INR (67% TTR) R 20mg qd W INR (57.8% TTR) Acute proximal DVT D: 1.1% W: 1.7% PE R: 1.7% W: 2.2% Major Bleeds D: 3.3% W: 3.6% Non-inferior (HR 0.79, p<0.001, equal major bleeds) ARISTOTLE A 5mg BID W INR (TTR 66%) Secondary prevention after 6-12 mos treatment of VTE A: 1.3% W :1.6% R: 5.6% W: 5.4% R: 2.1% W: 3.1% Superior (HR 0.79, p=0.01, fewer major bleeds) Time Therapeutic Range = TTR
20 Drawbacks to NOACs Cost: about $250 per month (no insurance) or copays of $20-50/month. No antidote Some drug interactions Long term (> 2years safety unknown) GI upset (some contain tartaric acid, to lower ph for adequate absorption-this can cause dyspepsia) Concomitant use of antiplatelet agents increases risk of bleeding two-fold Possibly higher risk of MI with Thrombin Inhibitors compared to Factor Xa inhibitors (Ann Intern Med: 2012;157(11): )
21 Black Box Warnings Factor Xa inhibitors-increased risk of stroke after discontinuation for nonvalvular atrial fibrillation HR of 1.5 compared to warfarin for rivaroxaban, p=0.026 Need to bridge when converting to warfarin Rivaroxaban-Epidural or spinal hematoma with use of epidurals, spinal puncture (hold rivaroxaban >18 hrs prior to pulling, and wait 6 hrs before resuming) Dabigatran-increased risk of acute coronary events (absolute risk MI/ACS 0.27%, relative risk 33%)
22 Effects on Coagulation Tests PT: increase or no change (not reliable) aptt: reliably increased. >80 sec at trough associated with increased risk of bleeding in afib pts Thrombin clotting time (TCT): increased (impractical-2 day turn around in many labs)
23 Management of anti-coagulant associated bleeding: HASHTI Hold further dose of Anticoagulant Consider Antidote Supportive treatment Local or Surgical Hemostatic measures Transfusion Investigate Source of Bleeding
24 Potential antidotes FFP-No clinical data, but decreased vol of intracerebral hemorrhage in mice with dabigatran Prothrombin Complex Concentrates (PCC): 3 Factor-II, IX, X, Prot C and S; 4 Factor- II, VII, IX, X, Prot C and S. Some minimal data in healthy subjects and animals Activated PCC: contains factors II, VII, IX and X, activated during manufacturing. Possible reversal in animal models Activated Charcoal-99.9% absorption of dabigatran if given within 2 hours of ingestion Recombinant Factor VIIa-developed for hemophiliacs-in develpment Hemodialysis-may not be feasible if patient is hemodynamically unstable
25 Drug Interactions-Dabigatran Drug Amiodarone % Atorvastatin +18% Clarithromycin,erythromycin % Dronedarone % Ketoconazole % Quinadine +50% Rifampin, phenytoin, St John s Wort, phenobarbital, carbamezepim % increase or decrease in serum concentration -66% Verapamil %
26 Drug Interactions-Rivaroxaban Drug Strong P-gp Inducers and CYP3A4 Inducers: Rifampin, phenytoin, St John s Wort, phenobarbital, Strong CYP3A4 Inhibitors and P-gp Inhibitors: Ketoconazole, Itraconazole Clarithromycin,erythromycin Fluconazole Recommendation Avoid use together Avoid use together Increases anticoagulant effect Increases anticoagulant effect
27 Drug Interactions-Apixaban Drug Strong P-gp Inducers and CYP3A4 Inducers: Rifampin, phenytoin, St John s Wort, phenobarbital, Strong CYP3A4 Inhibitors and P-gp Inhibitors: Ketoconazole, Itraconazole Clarithromycin,erythromycin Recommendation Avoid use together Reduce dose to 2.5mg BID Reduce dose to 2.5mg BID
28 Recommended Labs to follow All patients, annually: hemoglobin, renal and liver function panels CrCl ml/min or if >75 years old: renal function every 6 months CrCl ml/min: renal function every 3 months (contraindication for use of dabigatran) On an indication basis: recheck labs if a condition occurs that may change renal or hepatic function
29 Summary Novel anticoagulants provide a welcome alternative to warfarin based on ease of use, safety, and efficacy FDA approval for some venous indications is still pending Head to head trials would be needed to determine superiority/inferiority in treating and preventing VTE comparing Factor Xa and thrombin inhibitors (might be difficult-who is going to pay for these trials? Registries may help?) The first drug that has a reversal agent will gain significant advantage in the market of anticoagulants
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationClinical Assistant Professor University of Kansas School of Pharmacy. Objectives
New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Clinical Assistant Professor University of Kansas School of Pharmacy 1 Objectives Discuss the advantages and disadvantages of the new oral anticoagulants
More informationNovel Anticoagulants
Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota
More informationAnticoagulation Strategies: Are New Oral Anticoagulants Ready for Prime Time? B. Gail Macik, MD Professor of Medicine & Pathology
Anticoagulation Strategies: Are New Oral Anticoagulants Ready for Prime Time? Virginia American College of Physicians Annual Conference March 7, 2014 B. Gail Macik, MD Professor of Medicine & Pathology
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationDisclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis
TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received
More informationAnticoagulants. Denver Health April 12, 2011
New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis
More informationNew Oral Anticoagulants (NOACs)
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Janice Lawson, MD Tallahassee Memorial Hospital Cancer and Hematology Specialists Disclosure
More informationNew Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D.
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationOverview. Disclosures. Update on Anticoagulants. The Ideal Oral Anticoagulant. Warfarin. None
Update on Anticoagulants Jay Gaddy, MD, PhD Indiana Hemophilia & Thrombosis Center Indianapolis, Indiana None Disclosures Overview General discussion of anticoagulants New oral anticoagulants (NOACs) and
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationNew Anticoagulation Agents
New Anticoagulation Agents Use of New and Older Therapeutic Agents in the Treatment Regimen Michelle Geddes Case 1 40 year old woman with idiopathic proximal DVT. Previous heparin allergy (wheals, hives)
More informationAnticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice. B. Gail Macik, MD Professor of Medicine & Pathology
Anticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice Virginia Association of Hematology & Oncology Spring Meeting April 18, 2015 B. Gail Macik, MD Professor of Medicine
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationhttp://www.medscape.org/viewarticle/808338_print
Page 1 of 18 From Medscape Education Cardiology Pharmacokinetics of Anticoagulants: Why It Matters Matthew A. Cavender, MD, MPH; Robert P. Giugliano, MD, SM CME Released: 07/31/2013 ; Valid for credit
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationManagement of Bleeding and Practical Management of New Oral Anticoagulants
Management of Bleeding and Practical Management of New Oral Anticoagulants Anna Rahmani October 2, 2014 CONFLICT OF INTEREST:! NONE Overview: Background on the new oral anticoagulants (NOACs) Approved
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationNOACs 2013: Evolving Anticoagulation Options. Erik Yeo MD University Health Network University of Toronto
NOACs 2013: Evolving Anticoagulation Options Erik Yeo MD University Health Network University of Toronto Objectives Clinical overview the new oral anticoagulants and their management issues Rivaroxaban
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More information